Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Global X MSCI Argentina ETF (ARGT) Price & Performance

ADMA Biologics IncTrade
Global X MSCI Argentina ETFTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Global X MSCI Argentina ETF — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Global X MSCI Argentina ETF trades at $92.45. The key difference: Global X MSCI Argentina ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

ADMAARGT
Market Cap
$2.18B
Sector
HealthBroad Market / Factor
52-Week High
$20.38$102.94
52-Week Low
$7.60$67.55
Enterprise Value
$2.25B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Global X MSCI Argentina ETF

ARGT trades at $92.96, up 0.43% with a bearish technical signal from moving averages. The ETF shows neutral oscillators with RSI at 44.95. Recent Seeking Alpha analysis (June 18, 2026) highlights a 28% upside potential as Argentina's economic reforms progress, with the fund trading at 12.5x earnings below its post-Milei average.

The outlook suggests potential re-rating to 14-18x earnings could yield 12-44% upside, supported by Argentina's improving monetary backdrop. Key risks include country-specific volatility and concentrated holdings in MercadoLibre. Institutional interest is growing with Stanley Druckenmiller's recent position accumulation.

Returns comparison

Trailing returns across standard periods

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Global X MSCI Argentina ETF

ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.

Read more on ARGT